Uploaded December 2024 | Updated September 2026, 3 weeks ago

---

Caterina Marchiò, MD, PhD, spiega perché l'implementazione del test CGP (Comprehensive Genomic Profiling) nel proprio istituto, rispetto all'invio dei campioni a un servizio esterno, può offrire maggiori opportunità ai pazienti di cancro nell'ambito della medicina di precisione.

Caterina Marchiò, MD, PhD è professore di patologia presso l'Istituto Candiolo, Università di Torino, Italia.

Convidi il video in inglese: youtu.be/NErI9YCGcn4

Learn about in-house CGP including homologous recombination deficiency (HRD): youtu.be/qz9auYRPvV8

Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

View customer spotlight videos
youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79

View Illumina webinars
youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ

View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

LinkedIn: linkedin.com/company/illumina
X: https://x.com/illumina
Instagram: instagram.com/illuminainc
Facebook: facebook.com/illuminainc
TikTok: tiktok.com/@illuminainc

#CGP #MedicinadiPrecisione #Illumina